Objective  To observe the effects of sacubitril-valsartan tablets on the expressions of N terminal pro B type natriuretic peptide (NT-proBNP), troponin I (cTnI) and cardiac function in patients with chronic cardiac insufficiency.

Methods  Patients with chronic cardiac insufficiency who were diagnosed and treated in Beijing Friendship Hospital of Capital Medical University from November 2021 to December 2022 were selected as the study subjects, and were divided into the study group (sacubitril-valsartan tablets) and the control group (valsartan capsules) according to the random number table method. The total effective rate, cardiac function indexes [left ventricular ejection fraction (LVEF), left ventricular end systolic diameter (LVESD), left ventricular end-diastolic diameter (LEVDD)], plasma NT-proBNP, cTnI, soluble growth stimulation expression gene 2 protein (sST2), angiotensin (AngII) and the incidence of adverse reactions were observed in the two groups.

Results  A total of 100 patients with cardiac insufficiency were included in the study, with 50 in the study group and 50 in the control group. After treatment, the total effective rate of the study group was higher than that of the control group (P<0.05). The LVEF in the study group was significantly higher than that in the control group, while the LVESD, LEVDD were significantly lower than those in the control group (P<0.05). After treatment, the plasma of NT-proBNP, cTnI,  AngII, and sST2 in two groups had statistical difference (P<0.05) and the difference in the above indicators before and after treatment in two groups were statistically siginficant (P<0.05). The differences in adverse reactions between two groups were not statistically significant (P>0.05).

Conclusion  The treatment of chronic heart failure patients with sacubitril-valsartan tablets can improve heart function, prognosis, and safety.

1.董媛, 原巧宁, 杨永辉. 银杏叶片联合沙库巴曲缬沙坦治疗老年慢性心力衰竭的疗效及对血清NT-proBNP、MMP-9、IL-6和RBP4水平的影响[J]. 中国医师杂志, 2023, 25(9): 1373-1376. [Dong Y, Yuan QN, Yang YH. The therapeutic effect of Ginkgo biloba leaves combined with Shakubaqu valsartan in the treatment of elderly chronic heart failure and its impact on serum NT proBNP, MMP-9, IL-6, and RBP4 levels[J]. Journal of Chinese Physician, 2023, 25(9): 1373-1376.] DOI: 10. 3760/cma.j.cn431274-20220726-00737.

2.赵鲁静, 李传方, 张苒, 等. 沙库巴曲缬沙坦与缬沙坦治疗慢性心功能不全的疗效比较及对患者外周血单个核细胞锌指蛋白A20和核因子-κB的影响[J]. 中国医师进修杂志, 2022, 45(12): 1088-1092. [Zhao LJ, Li CF, Zhang R, et al. The efficacy comparison of sakubatril valsartan and valsartan in the treatment of patients with chronic cardiac insufficiency and the influence on zinc finger protein A20 and nuclear factor-κB in peripheral blood mononuclear cells[J]. Chinese Journal of Postgraduates of Medicine, 2022, 45(12): 1088-1092.] DOI: 10.3760/cma.j.cn115455-20210526-00704.

3.秦少强, 张占帅, 石金铮, 等. 沙库巴曲缬沙坦治疗老年慢性心功能不全的疗效及机制研究[J]. 实用老年医学, 2021, 35(8): 837-839, 848. [Qin SQ, Zhang ZS, Shi JZ, et al. Study on the efficacy and mechanism of sacubitril valsartan in the treatment of elderly patients with chronic heart failure[J]. Practical Geriatrics, 2021, 35(8): 837-839, 848.] DOI: 10.3969/j.issn.1003-9198.2021.08.012.

4.柴阿霞. 沙库巴曲缬沙坦治疗慢性心功能不全对患者血浆N末端脑钠肽前体心室重构及生存质量的影响[J]. 中国药物与临床, 2021, 21(17): 2992-2994. [Chai AX. The effect of Shakubaquvalsartan on plasma N-terminal pro-brain natriuretic peptide ventricular remodeling and quality of life in patients with chronic heart failure[J]. Chinese Remedies & Clinics, 2021, 21(17): 2992-2994.] DOI: 10.11655/zgywylc2021.17.033.

5.吴捷华, 谢卫星, 许涛, 等. 沙库巴曲缬沙坦对慢性心力衰竭患者躯体化症状及焦虑抑郁的影响[J]. 中国循证心血管医学杂志, 2022, 14(4): 439-441, 446. [Wu JH, Xie WX, Xu T, et al. Influence of sakubatril-valsartan on somatization symptoms, anxiety and depression in patients with chronic heart failure[J]. Chinese Journal of Evidence-Bases Cardiovascular Medicine, 2022, 14(4): 439-441, 446.] DOI: 10.3969/j.issn.1674-4055.2022.04.13.

6.中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 慢性心力衰竭诊断治疗指南[J]. 中华心血管病杂志, 2007, 35(12): 1076-1095. DOI: 10.3760/j.issn. 0253-3758.2007.12.002.

7.中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2014[J]. 中国实用乡村医生杂志, 2014, 1(24): 3-10. DOI: 10.3969/j.issn.1672-7185.2014.24.04.

8.国家卫生计生委合理用药专家委员会, 中国药师协会. 心力衰竭合理用药指南[J]. 中国医学前沿杂志(电子版), 2016, 8(9): 19-66. DOI: 10.12037/YXQY.2016.09-06.

9.王晓楠, 江莹, 康晓凤, 等. 健康合作者量表汉化及在慢性心力衰竭患者中的信效度检验研究[J]. 中国全科医学, 2022, 25(4): 497-504. [Wang XN, Jiang Y, Kang XF, et al. Reliability and validity of the chinese version of the partners in health scale in patients with chronic heart failure[J]. Chinese General Practice, 2022, 25(4): 497-504.] DOI: 10.12114/j.issn.1007-9572.2021.00.319.

10.徐学广, 赵洪刚. 脉君安片联合缬沙坦治疗中老年原发性高血压的临床研究[J]. 现代药物与临床, 2022, 37(2): 310-313. [Xu XG, Zhao HG. Clinical study on Maijunan tablets combined with valsartan in treatment of middle-aged and elderly patients with essential hypertension[J]. Drugs & Clinic, 2022, 37(2): 310-313.] DOI: 10.7501/j.issn.1674-5515.2022.02.014.

11.叶东旭, 余儒桓, 余守雅, 等. 我院心力衰竭患者沙库巴曲缬沙坦应用情况调查[J]. 中国药师, 2021, 24(4): 717-721. [Ye DX, Yu RH, Yu SY, et al. Investigation of the application status of sacubitril/valsartan in patients with heart failure in our hospital[J]. China Pharmacist, 2021, 24(4): 717-721.] DOI: 10.3969/j.issn.1008-049X. 2021.04.021.

12.姜红峰, 杜艳华, 黄蔡华. 沙库巴曲缬沙坦对老年慢性心力衰竭患者左心室重构和生活质量的影响[J]. 中华老年心脑血管病杂志, 2022, 24(3): 251-254. [Jiang HF, Du YH, Huang CH. The effect of Shakubaquvalsartan on left ventricular remodeling and quality of life in elderly patients with chronic heart failure[J]. Chinese Journal of Geriatric Heart Brain and Vessel Diseases, 2022, 24(3): 251-254.]. https://qikan.cqvip.com/Qikan/Article/Detail?id=7106866441.

13.张静, 陈巍, 付伟, 等. 沙库巴曲缬沙坦对老年慢性心力衰竭患者心力衰竭易损期心功能的影响[J]. 中华实用诊断与治疗杂志, 2021, 35(7): 735-738. [Zhang J, Chen W, Fu W, et al. Influence of sacubitril valsartan on the heart function in elderly chronic heart failure at vulnerable stage[J]. Journal of Chinese Practical Diagnosis and Therapy, 2021, 35(7): 735-738.] DOI: 10.13507/j.issn. 1674-3474.2021.07.021.

14.赵鲁静, 李传方, 张苒, 等. 沙库巴曲缬沙坦与缬沙坦治疗慢性心功能不全的疗效比较及对患者外周血单个核细胞锌指蛋白A20和核因子-κB的影响[J]. 中国医师进修杂志, 2022, 45(12): 1088-1092. [Zhao LJ, Li CF, Zhang R, et al. The efficacy comparison of sakubatril valsartan and valsartan in the treatment of patients with chronic cardiac insufficiency and the influence on zinc finger protein A20 and nuclear factor-κB in peripheral blood mononuclear cells[J]. Chinese Journal of Postgraduates of Medicine, 2022, 45(12): 1088-1092.] DOI: 10.3760/cma.j.cn115455-20210526-00704.

15.许振琦, 黄强, 范闻轩, 等. 早期创伤性颅脑损伤病人血浆NT-proBNP水平与疾病严重程度及预后的关系分析[J]. 蚌埠医学院学报, 2023, 48(3): 314-318. [Xu ZQ, Huang Q, Fan WX, et al. Analysis of relationship between plasma NT-proBNP level and disease severity and prognosis in patients with early traumatic craniocerebral injury[J]. Journal of Bengbu Medical College, 2023, 48(3): 314-318.] DOI: 10.13898/j.cnki.issn.1000-2200.2023. 03.008.

16.周苗, 翁嘉灏, 冯其茂, 等. 常规治疗加用温阳活血方对冠心病合并心衰患者心功能及远期预后的影响观察 [J]. 中国药师, 2022, 25(7): 1191-1194. [Zhou M, Weng JH, Feng QM, et al. Effects of routine treatment plus wenyang huoxue recipe on cardiac function and long-term prognosis of patients with coronary heart disease complicated with heart failure[J]. China Pharmacist, 2022, 25(7): 1191-1194.] DOI: 10.19962/j.cnki.issn1008-049X.2022.07.012.

17.孙媛媛, 余其贵, 鲁朝玉, 等. 心力衰竭超声指数联合血清肌钙蛋白Ⅰ、脑钠肽对老年舒张性心力衰竭患者不良心血管事件的预测价值分析[J]. 现代生物医学进展, 2021, 21(14): 2753-2757. [Sun YY, Yu QG, Lu CY, et al. Analysis of the predictive value of heart failure echocardiography index combined with serum troponin i and brain natriuretic peptide on adverse cardiovascular events in elderly patients with diastolic heart failure[J]. Progress in Modern Biomedicine, 2021, 21(14): 2753-2757.] DOI: 10.13241/j.cnki.pmb.2021.14.033.

18.刘壮壮, 黄宇理. 血清可溶性生长刺激表达基因2在慢性心力衰竭患者诊断与预后评估中的应用[J]. 南昌大学学报: 医学版, 2021, 61(1): 43-46. [Liu ZZ, Huang YL. Value of serum soluble growth stimulation expressed gene 2 in evaluation of diagnosis and prognosis of chronic heart failure[J]. Journal of Nanchang University (Medical Sciences), 2021, 61(1): 43-46.] DOI: 10.13764/j.cnki.ncdm.2021.01.009.